SAC platform · Strain engineering · Process development

SAC platform — from microbial resources to manufacturing.

One platform, four modules. The Synbio Agile Commercialization (SAC) platform links the Cutis Microbe Bank, KeySS key starting strains, the CutisBiofoundry and MtoM process development, so that an original strain becomes a patentable process and a material a partner can manufacture.

Conceptual microbial forms for the SAC platform

Strengths of the SAC platform

Scale-up becomes a near-term reality rather than a distant hope.

The SAC platform shortens the time needed to develop a promising molecule into a product that can be manufactured at commercial scale.

Translating laboratory results into manufacturing requires checking whether performance and quality can be maintained, and the process reproduced, as production scale changes. Reducing uncertainty during this transition is a key challenge in commercialization.

To address this challenge, CutisBio is building its own development programmes with clear criteria for deciding whether to proceed at each stage. The SAC platform connects these stages so that validation results can quickly inform the next step, supporting scale-up and technology transfer.

A development path with clear decision points.
  1. 01

    Define

    Target, application, performance needs, and the host and route strategy.

  2. 02

    Build

    Strain construction, pathway assembly and the first screening rounds.

  3. 03

    Validate

    Performance, identity and quality attributes confirmed at laboratory scale.

  4. 04

    Scale

    Fermentation and recovery developed as the programme progresses through its engineering and pilot stages.

  5. 05

    Transfer

    A documented, repeatable process handed to manufacturing and application.

Capabilities

What the platform covers.

Category-level capabilities that run across programmes. Programme-specific data is shared with qualified partners under NDA.

  • 01

    Host and strain engineering

    Selecting and engineering microbial hosts suited to the target and to the intended process.

  • 02

    Pathway and flux optimisation

    Designing biosynthetic routes and balancing metabolic flux towards the product.

  • 03

    Robotic high-throughput screening

    Comparing large libraries of variants in parallel on the biofoundry to select leads on the criteria that matter.

  • 04

    Fermentation development

    Cultivation strategy, control and characterisation, developed from laboratory scale onward.

  • 05

    Downstream and purification development

    Harvest, separation, purification and formulation designed for recovery and end use.

  • 06

    Analytical and quality methods

    Identity, purity and functional methods defined alongside the process, not after it.

  • 07

    Scale-up and technology transfer

    Stage-gated progression and documentation that a manufacturing partner can run from.

  • 08

    Application validation with partners

    Testing the material in the partner’s application and workflow before commercial commitment.

From platform to application

Explore the materials, products and services.

See the purpose and research context of each application. Product-specific specifications and development discussions are available through an inquiry.

Partner with CutisBio

Discuss a target molecule or material

Tell us the molecule or material, the application and the performance you need. We will come back with a view on feasibility, the platform route we would take and how to start.